Abstract
The “receptor conversion phenomenon” is a well-documented event during metastatic progression of breast cancer (BC), which result in Hormone Receptor and Human Epidermal Growth Factor Receptor 2 (HER2) status discordance between primary tumor and metastatic site. This phenotypic switch, related to tumor heterogeneity and/or change in cancer biology, may influence treatment plan in metastatic setting. Our retrospective analysis aimed to assess receptor status changes and their therapeutic and prognostic implications in a real word population.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
